Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044608 | 1.00 | HCRTR1 (0.45) | HCRTR1HCRTR2TDP1HPGDKMT2A | |
| SCHEMBL3058423 | 0.90 | BACE1 (0.42) | HCRTR1HCRTR2TDP1KMT2AMEN1 | |
| SCHEMBL3045276 | 0.90 | BACE1 (0.42) | HCRTR1HCRTR2TDP1KMT2AMEN1 | |
| SCHEMBL3045271 | 0.88 | HTR1A (0.47) | HCRTR1HCRTR2HPGDKMT2AMEN1 | |
| SCHEMBL3059938 | 0.88 | HTR1A (0.47) | HCRTR1HCRTR2HPGDKMT2AMEN1 | |
| SCHEMBL3058403 | 0.88 | HTR1A (0.47) | HCRTR1HCRTR2HPGDKMT2AMEN1 | |
| SCHEMBL3040844 | 0.87 | HCRTR1 (0.46) | HCRTR1HCRTR2KMT2AMEN1RAB9A | |
| SCHEMBL3042664 | 0.87 | HCRTR1 (0.46) | HCRTR1HCRTR2KMT2AMEN1RAB9A | |
| SCHEMBL3044603 | 0.85 | TDP1 (0.45) | HCRTR1HCRTR2TDP1HPGDKMT2A | |
| SCHEMBL3047220 | 0.85 | TDP1 (0.45) | HCRTR1HCRTR2TDP1HPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | NOVARTIS AG (CH) | 2010-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222396-A1 | 4-ARYL-BUTANE-1,3-DIAMIDES | CYP11B2, CYP11B1, BBC3 | HCRTR1 3230/4885HCRTR2 3029/4885TDP1 1379/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.